相关实验视频

Updated: May 5, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.9K

对患有急性髓性白血病的FLT3突变患者的综合分析与更新的2022年欧洲白血病网建议:来自土耳其AML注册项目的见解

Ibrahim Ethem Pinar1, Serhat Celik2, Merve Gokcen Polat3

  • 1Department of Hematology, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey.

BMC cancer
|October 11, 2025
PubMed
概括

经过修订的2022年欧洲白血病网络 (ELN) 对急性髓性白血病 (AML) 的分类,改善了风险分层,特别是对于具有fms类型的氨酸激酶3-内部协同重复 (FLT3-ITD) 突变的患者. 这份更新的指南提供了更具生物学一致性的分类,并支持量身定制的治疗方法.

关键词:
在 FLT3-ITD 突变中.急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.欧洲白血病网 欧洲白血病网预测值的预测值是指预测值的预测值.风险分层是指风险的分层.

更多相关视频

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

631
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

842

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81